Industry
Biotechnology
AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
Loading...
Open
3.03
Mkt cap
830M
Volume
3.2M
High
3.05
P/E Ratio
-4.61
52-wk high
6.05
Low
2.76
Div yield
N/A
52-wk low
2.33
Portfolio Pulse from
November 05, 2024 | 12:30 pm
Portfolio Pulse from Benzinga Newsdesk
October 22, 2024 | 12:28 pm
Portfolio Pulse from Benzinga Newsdesk
October 22, 2024 | 12:16 pm
Portfolio Pulse from Benzinga Newsdesk
October 04, 2024 | 1:02 pm
Portfolio Pulse from Avi Kapoor
August 20, 2024 | 1:45 pm
Portfolio Pulse from Benzinga Newsdesk
August 20, 2024 | 11:40 am
Portfolio Pulse from Benzinga Newsdesk
August 06, 2024 | 8:07 pm
Portfolio Pulse from Benzinga Newsdesk
July 31, 2024 | 1:11 pm
Portfolio Pulse from Benzinga Newsdesk
May 08, 2024 | 6:18 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.